Endoscopic healing is associated with a reduced risk of biologic treatment failure in patients with ulcerative colitis

Sci Rep. 2024 Jan 3;14(1):303. doi: 10.1038/s41598-024-51208-2.

Abstract

Increasing number of patients with ulcerative colitis (UC) have received biologic treatment during the last decade. The association between endoscopic healing (EH) and biologic treatment failure remains understudied. Medical information of UC patients who started biologic treatment was retrospectively collected. EH was defined as Mayo endoscopic subscore of 0 or 1. Loss of response (LOR)-free drug continuation rate was compared between patients who achieved EH and those who did not using Kaplan-Meier estimator. Fifty-two patients received 53 biologic treatments and underwent follow-up colonoscopies within 2 years. Thirty-three patients achieved EH, all of which remained on the same treatment without LOR during the observational period. Twenty patients did not achieve EH, 8 of which ultimately discontinued the treatment due to LOR to biologic agents. Kaplan-Meier estimator found a significantly lower drug continuation rate in patients without EH (p < 0.001; log-rank test). A Cox regression analysis identified EH as an independent factor associated with a reduced risk of LOR-related biologic treatment failure irrespective of the types of biologic agents (Hazard Ratio = 0.0324, p < 0.001). EH within 2 years is associated with a reduced risk of LOR-related biologic treatment failure in patients with UC.

MeSH terms

  • Biological Products* / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Colonoscopy
  • Humans
  • Intestinal Mucosa
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Failure

Substances

  • Biological Products